Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,
These observations are procedural in nature and none of them are related to data integrity
The FDA issued Form 483 with one observation related to building and facility management
The Q1 2025 also witnessed a successful launch of Allegra D
Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores
This significant milestone enhances our global regulatory standing
This recertification of Company's OECD GLP is testimony to company's unwavering commitment to maintain international quality standards at the facility
Vimta Labs has reported total income of Rs. 96.08 crores during the period ended March 31, 2025
This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.
The Subsidiary has received one inspectional observation in Form 483
Subscribe To Our Newsletter & Stay Updated
